ArticleEuropean journal of nuclear medicine and molecular imaging2022
Preclinical evaluation and pilot clinical study of [
Article in European journal of nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 40 citations in OpenAlex.
- Diagnostic accuracy ofEuropean journal of nuclear medicine and molecular imaging · 2026Article
- IntegratedEuropean journal of nuclear medicine and molecular imaging · 2026Article
- [Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Fibroblast Activation Protein Inhibitor (FAPI) PET: A Scoping Review of Emerging Oncologic and Fibroinflammatory Applications.Diagnostics (Basel, Switzerland) · 2026Review
- Article
- A FAPI-based small-molecule drug conjugate alleviates rheumatoid arthritis by targeting pathogenic FAPα-expressing fibroblasts.Acta pharmacologica Sinica · 2026Article
- Angelicin Inhibits NSCLC Tumor Growth via the Inhibition of Cancer-Associated Fibroblasts.Combinatorial chemistry & high throughput screening · 2026Article
- Targeting the synovial engine: next-generation engineered immune cells to eradicate pathogenic FLS in rheumatoid arthritis, with safety-first, selective designs.Frontiers in immunology · 2026Review
- Non-FDG PET/CT imaging of inflammatory arthritis.Skeletal radiology · 2025Review
- Fibroblast activation imaging in rheumatoid arthritis: evaluating disease activity and treatment response using [European radiology · 2025Article
- Fibroblast activation protein targeting radiopharmaceuticals: From drug design to clinical translation.Acta pharmaceutica Sinica. B · 2025Review
- The molar dose of FAPI administered impacts on the FAP-targeted PET imaging and therapy in mouse syngeneic tumor models.European journal of nuclear medicine and molecular imaging · 2025Article
- Clinical Utility ofMedComm · 2025Article
- CXCR4-targeted PET imaging in rheumatoid arthritis: a novel approach for monitoring disease activity and therapeutic response.EJNMMI research · 2025Article
- Targeting fibroblast activation protein in rheumatoid arthritis: from molecular imaging to precision therapeutics.Frontiers in immunology · 2025Review
- Current status of FAP-directed cancer theranostics: a bibliometric analysis.Biophysics reports · 2024Article
- Review
- Clinical applications of fibroblast activation protein inhibitor positron emission tomography (FAPI-PET).Npj imaging · 2024Review
- MSC-microvesicles protect cartilage from degradation in early rheumatoid arthritis via immunoregulation.Journal of nanobiotechnology · 2024Article
- Emerging Landscape ofACS pharmacology & translational science · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeFibroblast-like synoviocytes (FLSs) are key effector cells in the inflamed joints of patients with rheumatoid arthritis (RA). Previous studies have suggested that fibroblast activation protein (FAP) is highly expressed in RA-derived FLSs and is a specific marker of activated RA FLSs. In this study, we developed aluminum-[
methodsRA FLSs and NIH3T3 cells transfected with FAP were used to perform in vitro-binding studies. Biodistribution was conducted in normal DBA1 mice. Collagen-induced arthritis (CIA) models with different arthritis scores were subjected to [
resultsThe binding of [
conclusion[
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.